GRCE (Grace Therapeutics) Beginning Cash Position: $18.67 Mil (As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.45
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Beginning Cash Position?

Grace Therapeutics GRCE -2.20% 31 Beginning Cash Position is $18.67 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $18.67 Mil.

Grace Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($20.01 Mil) to Dec. 2025 ($16.86 Mil) but then increased from Dec. 2025 ($16.86 Mil) to Mar. 2026 ($18.67 Mil).

Grace Therapeutics's annual Beginning Cash Position declined from Mar. 2024 ($27.88 Mil) to Mar. 2025 ($23.01 Mil) and declined from Mar. 2025 ($23.01 Mil) to Mar. 2026 ($22.13 Mil).

Grace Therapeutics Beginning Cash Position Related Terms

Grace Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Beginning Cash Position Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.94 30.34 27.88 23.01 22.13

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.09 22.13 20.01 16.86 18.67
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $18.67 Mil mean?
Grace Therapeutics (GRCE) has a Beginning Cash Position of $18.67 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' Beginning Cash Position too high?
Grace Therapeutics' current Beginning Cash Position is $18.67 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Beginning Cash Position compare to INMB and ABVC?
Grace Therapeutics' Beginning Cash Position of $18.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Beginning Cash Position is $18.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Beginning Cash Position of $18.67 Mil. The current Beginning Cash Position is $18.67 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Beginning Cash Position is $18.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.45
Price